West Pharmaceutical Services, Inc. (NYSE:WST) Shares Acquired by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC lifted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 8.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,301 shares of the medical instruments supplier’s stock after purchasing an additional 105 shares during the period. Elevated Capital Advisors LLC’s holdings in West Pharmaceutical Services were worth $391,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in WST. Wellington Management Group LLP increased its position in shares of West Pharmaceutical Services by 60.5% during the fourth quarter. Wellington Management Group LLP now owns 5,837 shares of the medical instruments supplier’s stock worth $2,055,000 after purchasing an additional 2,201 shares in the last quarter. Gateway Investment Advisers LLC purchased a new position in shares of West Pharmaceutical Services during the first quarter worth about $596,000. Kingswood Wealth Advisors LLC grew its holdings in shares of West Pharmaceutical Services by 4.4% during the first quarter. Kingswood Wealth Advisors LLC now owns 2,466 shares of the medical instruments supplier’s stock worth $976,000 after buying an additional 103 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new position in shares of West Pharmaceutical Services during the first quarter worth about $398,000. Finally, Blue Zone Wealth Advisors LLC purchased a new position in shares of West Pharmaceutical Services during the first quarter worth about $3,841,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Insider Buying and Selling

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $286.44 on Thursday. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70. The business’s 50-day moving average price is $299.72 and its 200 day moving average price is $323.06. The firm has a market cap of $20.78 billion, a P/E ratio of 40.75, a P/E/G ratio of 10.21 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. During the same period in the prior year, the business earned $2.11 EPS. The business’s quarterly revenue was down 6.9% compared to the same quarter last year. On average, equities research analysts expect that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.